← Back to patent-cliff list
Sovateltide
Tier C — Watch / tradeSovateltide
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：ETBR
Brand：Tyvalzi
Indications (approved)：Ischaemic stroke
Regional status
US
Phase III
2025-07-24
EU
Phase III
2025-07-24
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sovateltide?
Approved indications include: Ischaemic stroke.
When does the Sovateltide patent expire?
No public expiry year is available for Sovateltide yet; this page updates once verified.
How do I get a quote for Sovateltide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27